The implication of adiponectin and resistin in gastrointestinal diseases

Cytokine and Growth Factor Reviews

Volumn 22, Issue 2, 2011, Pages 109-119

  Tiaka, Elisavet K ^a   Manolakis, Anastassios C ^a   Kapsoritakis, Andreas N ^a   Potamianos, Spyros P ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

Adipokines; Adiponectin; Gastrointestinal diseases; Obesity; Resistin

Indexed keywords

ADIPONECTIN; CORTICOSTEROID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; RESISTIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; BACTERIAL COLONIZATION; BARRETT ESOPHAGUS; CANCER INHIBITION; CANCER RISK; CARCINOGENESIS; CELL PROLIFERATION; COLITIS; COLON CANCER; COLON DISEASE; CROHN DISEASE; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; ENTERITIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INFECTION; HELICOBACTER INFECTION; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HUMAN; IMMUNOPATHOGENESIS; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; SMALL INTESTINE CANCER; SMALL INTESTINE DISEASE; STOMACH CANCER; STOMACH DISEASE; UPREGULATION;

ADIPONECTIN; ANIMALS; COLONIC DISEASES; COLONIC NEOPLASMS; DOWN-REGULATION; ESOPHAGEAL DISEASES; GASTROINTESTINAL DISEASES; GASTROINTESTINAL NEOPLASMS; HUMANS; OBESITY; REPERFUSION INJURY; RESISTIN; STOMACH DISEASES; UP-REGULATION;

EID: 79957768992     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2011.04.002     Document Type: Review

References (149)

1. Trayhurn P., Beattie J.H. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001, 60:329-339.
2. Trayhurn P., Wood S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004, 92:347-355.
3. Trayhurn P., Wood I.S. Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem Soc Trans 2005, 33:1078-1081.
4. Frühbeck G., Gómez-Ambrosi J., Muruzábal F.J., Burrell M.A. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab 2001, 280:E827-E847.
5. Rajala M.W., Scherer P.E. Minireview: the adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003, 144:3765-3773.
6. Hauner H. Secretory factors from human adipose tissue and their functional role. Proc Nutr Soc 2005, 64:163-169.
7. Wozniak S., Gee L., Wachtel M., Frezza E. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci 2009, 54:1847-1856.
8. Goldfine A.B., Kahn C.R. Adiponectin: linking the fat cell to insulin sensitivity. Lancet 2003, 362:1431-1432.
9. Meier U., Gressner A. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 2004, 50:1511-1525.
10. Renehan A., Roberts D., Dive C. Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem 2008, 114:71-83.
11. Corbetta S., Bulfamante G., Cortelazzi D., Barresi V., Cetin I., Mantovani G., et al. Adiponectin expression in human fetal tissues during mid- and late gestation. J Clin Endocrinol Metab 2005, 90:2397-2402.
12. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006, 116:1784-1792.
13. Mao X., Kikani C.K., Riojas R.A., Langlais P., Wang L., Ramos F.J., et al. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol 2006, 8:516-523.
14. Tsuchida A., Yamauchi T., Kadowaki T. Nuclear receptors as targets for drug development: molecular mechanisms for regulation of obesity and insulin resistance by peroxisome proliferator-activated receptor, CREB-binding protein, and adiponectin. J Pharmacol Sci 2005, 97:164-170.
15. Koerner A., Kratzsch J., Kiess W. Adipocytokines: leptin-the classical, resistin-the controversical, adiponectin-the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005, 19:525-546.
16. Tilg H., Moschen A.R. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci 2008, 114:275-288.
17. Bruun J.M., Lihn A.S., Verdich C., Pedersen S.B., Toubro S., Astrup A., et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003, 285:E527-E533.
18. Ogunwobi O.O., Beales I.L. Adiponectin stimulates proliferation and cytokine secretion in colonic epithelial cells. Regul Pept 2006, 134:105-113.
19. Kato H., Kashiwagi H., Shiraga M., Tadokoro S., Kamae T., Ujiie H., et al. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol 2006, 26:224-230.
20. Matsuo Y., Imanishi T., Kuroi A., Kitabata H., Kubo T., Hayashi Y., et al. Effects of plasma adiponectin levels on the number and function of endothelial progenitor cells in patients with coronary artery disease. Circ J 2007, 71:1376-1382.
21. Ouedraogo R., Wu X., Xu S.Q., Fuchsel L., Motoshima H., Mahadev K., et al. Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. Diabetes 2006, 55:1840-1846.
22. Matarese G., Mantxoros C., La Cava A. Leptin and adipocytokines: bridging the gap between immunity and atherosclerosis. Curr Pharm Des 2007, 13:3676-3680.
23. Fenton J., Birmingham J., Hursting S., Hord N. Adiponectin blocks multiple signaling cascades associated with leptin-induced cell proliferation in ApcMin/1 colon epithelial cells. Int J Cancer 2008, 122:2437-2445.
24. Bastard J.P., Maachi M., Lagathu C., Kim M.J., Caron M., Vidal H., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006, 17:4-12.
25. Lago F., Dieguez C., Gómez-Reino J., Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 2007, 18:313-325.
26. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., et al. The hormone resistin links obesity to diabetes. Nature 2001, 409:307-312.
27. Kusminski C.M., McTernan P.G., Kumar S. Role of resistin in obesity, insulin resistance and type II diabetes. Clin Sci 2005, 109:243-256.
28. Jackson M.B., Osei S.Y., Ahima R.S. The endocrine role of adipose tissue: focus on adiponectin and resistin. Cur Opin Endocrinol Diab 2005, 12:163.
29. Lehrke M., Reilly M., Millington C.S., Iqbal N., Rader D.J., Lazar M.A. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004, 1:e45.
30. Iwasaki E., Suzuki H., Sugino Y., Iida T., Nishizawa T., Masaoka T., et al. Decreased levels of adiponectin in obese patients with gastroesophageal reflux evaluated by videoesophagography: possible relationship between gastroesophageal reflux and metabolic syndrome. J Gastroenterol Hepatol 2008, 23:S216-S221.
31. Rubenstein J.H., Dahlkemper A., Kao J.Y., Zhang M., Morgenstern H., McMahon L., et al. A pilot study of the association of low plasma adiponectin and Barrett's esophagus. Am J Gastroenterol 2008, 103:1358-1364.
32. Rubenstein J.H., Kao J.Y., Madanick R.D., Zhang M., Wang M., Spacek M.B., et al. Association of adiponectin multimers with Barrett's oesophagus. Gut 2009, 58:1583-1589.
33. Thompson O.M., Beresford S.A., Kirk E.A., Bronner M.P., Vaughan T.L. Serum leptin and adiponectin levels and risk of Barrett's esophagus and intestinal metaplasia of the gastroesophageal junction. Obesity (Silver Spring) 2010, 18:2204-2211.
34. Ryan A.M., Healy L.A., Power D.G., Byrne M., Murphy S., Byrne P.J., et al. Barrett esophagus: prevalence of central adiposity, metabolic syndrome, and a proinflammatory state. Ann Surg 2008, 247:909-915.
35. Konturek P.C., Burnat G., Rau T., Hahn E.G., Konturek S. Effect of adiponectin and ghrelin on apoptosis of Barrett adenocarcinoma cell line. Dig Dis Sci 2008, 53:597-605.
36. Ogunwobi O.O., Beales I.L. Globular adiponectin, acting via adiponectin receptor-1, inhibits leptin-stimulated oesophageal adenocarcinoma cell proliferation. Mol Cell Endocrinol 2008, 285:43-50.
37. Howard J.M., Beddy P., Ennis D., Keogan M., Pidgeon G.P., Reynolds J.V. Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma. Br J Surg 2010, 97:1020-1027.
38. Skinner D.B., Walther B.C., Riddell R.H., Schmidt H., Iascone C., DeMeester T.R. Barrett's esophagus. Comparison of benign and malignant cases. Ann Surg 1983, 198:554-565.
39. Zheng L., Tong Q., Weng M., He J., Lv Q., Wu Z., et al. Expression of resistin-like molecule beta in Barrett's esophagus: a novel biomarker for metaplastic epithelium. Dig Dis Sci 2010, 55:32-39.
40. Yildirim A., Bilici M., Cayir K., Yanmaz V., Yildirim S., Tekin S.B. Serum adiponectin levels in patients with esophageal cancer. Jpn J Clin Oncol 2009, 39:92-96.
41. Nakajima T.E., Yamada Y., Hamano T., Furuta K., Oda I., Kato H., et al. Adipocytokines and squamous cell carcinoma of the esophagus. J Cancer Res Clin Oncol 2010, 136:261-266.
42. Mueller A., O'Rourke J., Chu P., Kim C.C., Sutton P., Lee A., et al. Protective immunity against Helicobacter is characterized by a unique transcriptional signature. Proc Natl Acad Sci USA 2003, 100:12289-12294.
43. Torisu T., Takata Y., Ansai T., Matsumoto T., Sonoki K., Soh I., et al. Possible association of atrophic gastritis and arterial stiffness in healthy middle-aged Japanese. J Atheroscler Thromb 2009, 16:691-697.
44. Ishikawa M., Kitayama J., Kazama S., Hiramatsu T., Hatano K., Nagawa H. Plasma adiponectin and gastric cancer. Clin Cancer Res 2005, 11:466-472.
45. Kubota N., Terauchi Y., Yamauchi T., Kubota T., Moroi M., Matsui J., et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002, 277:25863-25866.
46. Brakenhielm E., Veitonmaki N., Cao R., Kihara S., Matsuzawa Y., Zhivotovsky B., et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA 2004, 101:2476-2481.
47. Motoshima H., Wu X., Mahadev K., Goldstein B.J. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 2004, 315:264-271.
48. Ishikawa M., Kitayama J., Yamauchi T., Kadowaki T., Maki T., Miyato H., et al. Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. Cancer Sci 2007, 98:1120-1127.
49. Otani K., Kitayama J., Kamei T., Soma D., Miyato H., Yamauchi T., et al. Adiponectin receptors are downregulated in human gastric cancer. J Gastroenterol 2010, 45:918-927.
50. Barresi V., Grosso M., Giuffrè G., Tuccari G., Barresi G. The expression of adiponectin receptors Adipo-R1 and Adipo-R2 is associated with an intestinal histotype and longer survival in gastric carcinoma. J Clin Pathol 2009, 62:705-709.
51. Maehara Y., Emi Y., Baba H., Adachi Y., Akazawa K., Ichiyoshi Y., et al. Recurrences and related characteristics of gastric cancer. Br J Cancer 1996, 74:975-979.
52. Adachi Y., Oshiro T., Mori M., Maehara Y., Sugimachi K. Prediction of early and late recurrence after curative resection for gastric carcinoma. Cancer 1996, 77:2445-2448.
53. Yoo C.H., Noh S.H., Shin D.W., Choi S.H., Min J.S. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000, 87:236-242.
54. Nakajima T.E., Yamada Y., Hamano T., Furuta K., Gotoda T., Katai H., et al. Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol 2009, 44:685-690.
55. Kitayama J., Tabuchi M., Tsurita G., Ishikawa M., Otani K., Nagawa H. Adiposity and gastrointestinal malignancy. Digestion 2009, 79(Suppl. 1):26-32.
56. Kerem M., Ferahkose Z., Yilmaz U.T., Pasaoglu H., Ofluoglu E., Bedirli A., et al. Adipokines and ghrelin in gastric cancer cachexia. World J Gastroenterol 2008, 14:3633-3641.
57. Zheng L., Weng M., He J., Yang X., Jiang G., Tong Q. Expression of resistin-like molecule beta in gastric cancer: its relationship with clinicopathological parameters and prognosis. Virchows Arch 2010, 456:53-63.
58. Norkina O., Kaur S., Ziemer D., De Lisle R.C. Inflammation of the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 2004, 286:G1032-G1041.
59. Nakagawa H., Tsunooka N., Yamamoto Y., Yoshida M., Nakata T., Kawachi K. Intestinal ischemia/reperfusion-induced bacterial translocation and lung injury in atherosclerotic rats with hypoadiponectinemia. Surgery 2009, 145:48-56.
60. Otani K., Kitayama J., Yasuda K., Nio Y., Iwabu M., Okudaira S., et al. Adiponectin suppresses tumorigenesis in Apc(Min)(/+) mice. Cancer Lett 2010, 288:177-182.
61. Steppan C.M., Brown E.J., Wright C.M., Bhat S., Banerjee R.R., Dai C.Y., et al. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA 2001, 98:502-506.
62. He W., Wang M.L., Jiang H.Q., Steppan C.M., Shin M.E., Thurnheer M.C., et al. Bacterial colonization leads to the colonic secretion of RELMβ/FIZZ2, a novel goblet cell-specific protein. Gastroenterology 2003, 125:1388-1397.
63. Nair M.G., Guild K.J., Du Y., Zaph C., Yancopoulos G.D., Valenzuela D.M., et al. Goblet cell-derived resistin-like molecule beta augments CD4+ T cell production of IFN-gamma and infection-induced intestinal inflammation. J Immunol 2008, 181:4709-4715.
64. Artis D., Wang M.L., Keilbaugh S.A., He W., Brenes M., Swain G.P., et al. RELMbeta/FIZZ2 is a goblet cell-specific immune-effector molecule in the gastrointestinal tract. Proc Natl Acad Sci USA 2004, 101:13596-13600.
65. Artis D. New weapons in the war on worms: identification of putative mechanisms of immune-mediated expulsion of gastrointestinal nematodes. Int J Parasitol 2006, 36:723-733.
66. Pesce J.T., Ramalingam T.R., Wilson M.S., Mentink-Kane M.M., Thompson R.W., Cheever A.W., et al. Retnla (relmalpha/fizz1) suppresses helminth-induced Th2-type immunity. PLoS Pathog 2009, 5:e1000393.
67. Herbert D.R., Yang J.Q., Hogan S.P., Groschwitz K., Khodoun M., Munitz A., et al. Intestinal epithelial cell secretion of RELM-beta protects against gastrointestinal worm infection. J Exp Med 2009, 206:2947-2957.
68. Karmiris K., Koutroubakis I., Kouroumalis E. Leptin, adiponectin, resistin, and ghrelin-implications for inflammatory bowel disease. Mol Nutr Food Res 2008, 52:855-866.
69. Fantuzzi G. Adiponectin and inflammation: consensus and controversy. J Allergy Clin Immunol 2008, 121:326-330.
70. Schäffler A., Schölmerich J. The role of adiponectin in inflammatory gastrointestinal diseases. Gut 2009, 58317-58322.
71. Nishihara T., Matsuda M., Araki H., Oshima K., Kihara S., Funahashi T., et al. Effect of adiponectin on murine colitis induced by dextran sulfate sodium. Gastroenterology 2006, 131:853-861.
72. Matsunaga H., Hokari R., Kurihara C., Okada Y., Takebayashi K., Okudaira K., et al. Omega-3 fatty acids exacerbate DSS-induced colitis through decreased adiponectin in colonic subepithelial myofibroblasts. Inflamm Bowel Dis 2008, 14:1348-1357.
73. Maeda N., Takahashi M., Funahashi T., Kihara S., Nishizawa H., Kishida K., et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001, 50:2094-2099.
74. Nakajima A., Wada K., Katayama K., Saubermann L., Osawa E., Nagase H., et al. Gene expression profile after PPAR-gamma ligand administration in DSS mice. J Gastrenterol 2002, Suppl. 14:62-66.
75. Katayama K., Wada K., Nakajima A., Mizuguchi H., Hayakawa T., Nakagawa S., et al. A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology 2003, 124:1315-1324.
76. Fayad R., Pini M., Sennello J.A., Cabay R.J., Chan L., Xu A., et al. Adiponectin deficiency protects mice from chemically induced colonic inflammation. Gastroenterology 2007, 132:601-614.
77. Bohn E., Bechtold O., Zahir N., Frick J.S., Reimann J., Jilge B., et al. Host gene expression in the colon of gnotobiotic interleukin-2-deficient mice colonized with commensal colitogenic or noncolitogenic bacterial strains: common patterns and bacteria strain specific signatures. Inflamm Bowel Dis 2006, 12:853-862.
78. Desreumaux P., Dubuquoy L., Nutten S., Peuchmaur M., Englaro W., Schoonjans K., et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 2001, 193:827-838.
79. Gambero A., Maróstica M., Abdalla Saad M.J., Pedrazzoli J. Mesenteric adipose tissue alterations resulting from experimental reactivated colitis. Inflamm Bowel Dis 2007, 13:1357-1364.
80. Thomaz M.A., Acedo S.C., de Oliveira C.C., Pereira J.A., Priolli D.G., Saad M.J., et al. Methotrexate is effective in reactivated colitis and reduces inflammatory alterations in mesenteric adipose tissue during intestinal inflammation. Pharmacol Res 2009, 60:341-346.
81. Ando Y., Inaba M., Sakaguchi Y., Tsuda M., Quan G.K., Omae M., et al. Subcutaneous adipose tissue-derived stem cells facilitate colonic mucosal recovery from 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats. Inflamm Bowel Dis 2008, 14:826-838.
82. Gove M.E., Pini M., Fayad R., Cabay R.J., Fantuzzi G. Adiponectin deficiency modulates adhesion molecules expression and cytokine production but does not affect disease severity in the transfer model of colitis. Cytokine 2009, 47:119-125.
83. Pini M., Gove M.E., Fayad R., Cabay R.J., Fantuzzi G. Adiponectin deficiency does not affect development and progression of spontaneous colitis in IL-10 knockout mice. Am J Physiol Gastrointest Liver Physiol 2009, 296:G382-G387.
84. Yamamoto K., Kiyohara T., Murayama Y., Kihara S., Okamoto Y., Funahashi T., et al. Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut 2005, 54:789-796.
85. Rogler G., Andus T. Cytokines in inflammatory bowel disease. World J Surg 1998, 22:382-389.
86. Motomura Y., Khan W.I., El-Sharkawy R.T., Verma-Gandhu M., Verdu E.F., Gauldie J., et al. Induction of a fibrogenic response in mouse colon by overexpression of monocyte chemoattractant protein-1. Gut 2006, 55:662-670.
87. Dubuquoy L., Dharancy S., Nutten S., Pettersson S., Auwerx J., Desreumaux P. Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet 2002, 360:1410-1418.
88. Lehrke M., Lazar M.A. Inflamed about obesity. Nat Med 2004, 10:126-127.
89. Barbier M., Vidal H., Desreumaux P., Dubuquoy L., Bourreille A., Colombel J.F., et al. Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. Gastroenterol Clin Biol 2003, 27:987-991.
90. Paul G., Schäffler A., Neumeier M., Fürst A., Bataillle F., Buechler C., et al. Profiling adipocytokine secretion from creeping fat in Crohn's disease. Inflamm Bowel Dis 2006, 12:471-477.
91. Karmiris K., Koutroubakis I., Xidakis C., Polychronaki M., Voudouri T., Kouroumalis E. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis 2006, 12:100-105.
92. Weigert J., Obermeier F., Neumeier M., Wanninger J., Filarsky M., Bauer S., et al. Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn's disease. Inflamm Bowel Dis 2010, 16:630-637.
93. Valentini L., Wirth E.K., Schweizer U., Hengstermann S., Schaper L., Koernicke T., et al. Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease. Nutrition 2009, 25:172-181.
94. Jürimäe J., Kums T., Jürimäe T. Adipocytokine and ghrelin levels in relation to bone mineral density in physically active older women: longitudinal associations. Eur J Endocrinol 2009, 160:381-385.
95. Basurto L., Galván R., Cordova N., Saucedo R., Vargas C., Campos S., et al. Adiponectin is associated with low bone mineral density in elderly men. Eur J Endocrinol 2009, 160:289-293.
96. Karmiris K., Koutroubakis I.E., Xidakis C., Polychronaki M., Kouroumalis E.A. The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2007, 19:789-794.
97. Munitz A., Waddell A., Seidu L., Cole E.T., Ahrens R., Hogan S.P., et al. Resistin-like molecule alpha enhances myeloid cell activation and promotes colitis. J Allergy Clin Immunol 2008, 122:1200-1207. e1.
98. Munitz A., Seidu L., Cole E.T., Ahrens R., Hogan S.P., Rothenberg M.E. Resistin-like molecule alpha decreases glucose tolerance during intestinal inflammation. J Immunol 2009, 182:2357-2363.
99. Te Velde A.A., Pronk I., de Kort F., Stokkers P.C. Glutathione peroxidase 2 and aquaporin 8 as new markers for colonic inflammation in experimental colitis and inflammatory bowel diseases: an important role for H2O2?. Eur J Gastroenterol Hepatol 2008, 20:555-560.
100. Hogan S., Seidu L., Blanchard C., Groschwitz K., Mishra A., Karow M.L. Resistin-like molecule β regulates innate colonic function: barrier integrity and inflammation susceptibility. J Allergy Clin Immunol 2006, 118:257-268.
101. McVay L., Keilbaugh S., Wong T., Kierstein S., Shin M.E., Lehrke M., et al. Absence of bacterially induced RELMβ reduces injury in the dextran sodium sulfate model of colitis. J Clin Invest 2006, 116:2914-2923.
102. Krimi R.B., Kotelevets L., Dubuquoy L., Plaisancie P., Walker F., Lehy T., et al. Resistin-like molecule β regulates intestinal mucous secretion and curtails TNBS-induced colitis in mice. Inflamm Bowel Dis 2008, 14:931-941.
103. Steppan C.M., Lazar M.A. The current biology of resistin. J Int Med 2004, 255:439-447.
104. Konrad A., Lehrke M., Schachinger V., Seibold F., Stark R., Ochsenkühn T., et al. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol 2007, 19:1070-1074.
105. Kaser S., Kaser A., Sandhofer A., Ebenbichler C.F., Tilg H., Patsch J.R. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003, 309:286-290.
106. Silswal N., Singh A.K., Aruna B., Mukhopadhyay S., Ghosh S., Ehtesham N.Z. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun 2005, 334:1092-1101.
107. Pischon T., Nöthlings U., Boeing H. Obesity and cancer. Proc Nutr Soc 2008, 67:128-145.
108. Fenton J.I., Birmingham J.M. Adipokine regulation of colon cancer: adiponectin attenuates interleukin-6-induced colon carcinoma cell proliferation via STAT-3. Mol Carcinog 2010, 49:700-709.
109. Sugiyama M., Takahashi H., Hosono K., Endo H., Kato S., Yoneda K., et al. Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int J Oncol 2009, 34:339-344.
110. Nishihara T., Baba M., Matsuda M., Inoue M., Nishizawa Y., Fukuhara A., et al. Adiponectin deficiency enhances colorectal carcinogenesis and liver tumor formation induced by azoxymethane in mice. World J Gastroenterol 2008, 14:6473-6480.
111. Zakikhani M., Dowling R.J., Sonenberg N., Pollak M.N. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila PA) 2008, 1:369-375.
112. Cowey S., Hardy R.W. The metabolic syndrome: a high-risk state for cancer?. Am J Pathol 2006, 169:1505-1522.
113. Byrne G.J., Ghellal A., Iddon J., Blann A.D., Venizelos V., Kumar S., et al. Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. J Natl Cancer Inst 2000, 92:1329-1336.
114. Chen J., Huang X.F. The signal pathways in azoxymethane-induced colon cancer and preventive implications. Cancer Biol Ther 2009, 8:1313-1317.
115. Raju J., McCarthy B., Bird R.P. Steady state levels of transforming growth factor-beta 1 and beta 2 mRNA and protein expression are elevated in colonic tumors in vivo irrespective of dietary lipids intervention. Int J Cancer 2002, 100:635-641.
116. Raju J., Bird R.P. Energy restriction reduces the number of advanced aberrant crypt foci and attenuates the expression of colonic transforming growth factor beta and cyclooxygenase isoforms in Zucker obese (fa/fa) rats. Cancer Res 2003, 63:6595-6601.
117. Yasuda Y., Shimizu M., Shirakami Y., Sakai H., Kubota M., Hata K., et al. Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Cancer Sci 2010, 101:1701-1707.
118. Asp M.L., Tian M., Wendel A.A., Belury M.A. Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice. Int J Cancer 2010, 126:756-763.
119. Ealey K.N., Archer M.C. Elevated circulating adiponectin and elevated insulin sensitivity in adiponectin transgenic mice are not associated with reduced susceptibility to colon carcinogenesis. Int J Cancer 2009, 124:2226-2230.
120. Kim A.Y., Lee Y.S., Kim K.H., Lee J.H., Lee H.K., Jang S.H., et al. Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol Endocrinol 2010, 24:1441-1452.
121. Drew J.E., Farquharson A.J., Padidar S., Duthie G.G., Mercer J.G., Arthur J.R., et al. Insulin, leptin, and adiponectin receptors in colon: regulation relative to differing body adiposity independent of diet and in response to dimethylhydrazine. Am J Physiol Gastrointest Liver Physiol 2007, 293:G682-G691.
122. Barb D., Williams C., Neuwirth A., Mantzoros C. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr 2007, 86:S858-S866.
123. Yoneda K., Tomimoto A., Endo H., Iida H., Sugiyama M., Takahashi H., et al. Expression of adiponectin receptors, AdipoR1 and AdipoR2, in normal colon epithelium and colon cancer tissue. Oncol Rep 2008, 20:479-483.
124. Yamaji T., Iwasaki M., Sasazuki S., Tsugane S. Interaction between adiponectin and leptin influences the risk of colorectal adenoma. Cancer Res 2010, 70:5430-5437.
125. Wei E.K., Giovannucci E., Fuchs C.S., Willett W.C., Mantzoros C.S. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 2005, 97:1688-1694.
126. Guadagni F., Roselli M., Martini F., Spila A., Riondino S., D'Alessandro R., et al. Prognostic significance of serum adipokine levels in colorectal cancer patients. Anticancer Res 2009, 29:3321-3327.
127. Kumor A., Daniel P., Pietruczuk M., Małecka-Panas E. Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma patients. Int J Colorectal Dis 2009, 24:275-281.
128. Gonullu G., Kahraman H., Bedir A., Bektas A., Yücel I. Association between adiponectin, resistin, insulin resistance, and colorectal tumors. Int J Colorectal Dis 2010, 25:205-212.
129. Lukanova A., Soderberg S., Kaaks R., Jellum E., Stattin P. Serum adiponectin is not associated with risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2006, 15:401-402.
130. Wolf I., Sadetzki S., Kanety H., Kundel Y., Pariente C., Epstein N., et al. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer 2006, 106:966-973.
131. Kaklamani V.G., Wisinski K.B., Sadim M., Gulden C., Do A., Offit K., et al. Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. JAMA 2008, 300:1523-1531.
132. Carvajal-Carmona L.G., Spain S., Kerr D., Houlston R., Cazier J.B., Tomlinson I. Common variation at the adiponectin locus is not associated with colorectal cancer risk in the UK. Hum Mol Genet 2009, 18:1889-1892.
133. Zheng L.D., Tong Q.S., Weng M.X., He J., Lv Q., Pu J.R., et al. Enhanced expression of resistin-like molecule beta in human colon cancer and its clinical significance. Dig Dis Sci 2009, 54:274-281.
134. Pechlivanis S., Lorenzo Bermejo J., Pardini B., Naccarati A., Vodickova L., Novotny J., et al. Genetic variation in adipokine genes and risk of colorectal cancer. Eur J Endocrinol 2009, 161:211.
135. Al-Harithy R.N., Al-Ghafari A.B. Resistin in human colon cancer. Increased expression independently of resistin promoter C-180G genotype. Saudi Med J 2010, 31:495-500.
136. Nagajyothi F., Desruisseaux M.S., Thiruvur N. Trypanosoma cruzi infection of cultured adipocytes results in an inflammatory phenotype. Obesity (Silver Spring) 2008, 16:1992-1997.
137. Otaka M., Konishi N., Odashima M., Jin M., Wada I., Matsuhashi T., et al. Effect of alcohol consumption on leptin level in serum, adipose tissue, and gastric mucosa. Dig Dis Sci 2007, 52:3066-3069.
138. Adeyemi E.O., Bastaki S.A., Chandranath I.S., Hasan M.Y., Fahim M., Adem A. Mechanisms of action of leptin in preventing gastric ulcer. World J Gastroenterol 2005, 11:4154-4160.
139. Shai I., Rimm E.B., Schulze M.B., Rifai N., Stampfer M.J., Hu F.B. Moderate alcohol intake and markers of inflammation and endothelial dysfunction among diabetic men. Diabetologia 2004, 47:1760-1767.
140. Pravdová E., Macho L., Hlavácová N., Ficková M. Long-time alcohol intake modifies resistin secretion and expression of resistin gene in adipose tissue. Gen Physiol Biophys 2007, 26:221-229.
141. Beulens J.W., van Beers R.M., Stolk R.P., Schaafsma G., Hendriks H.F. The effect of moderate alcohol consumption on fat distribution and adipocytokines. Obesity (Silver Spring) 2006, 14:60-66.
142. Motawi T.K., Abd Elgawad H.M., Shahin N.N. Gastroprotective effect of leptin in indomethacin-induced gastric injury. J Biomed Sci 2008, 15:405-412.
143. Takahashi S., Ushida M., Komine R., Shimizu A., Uchida T., Ishihara H., et al. Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. Thromb Res 2007, 119:517-524.
144. Tsuboi H., Sugimoto Y., Kainoh T., Ichikawa A. Prostanoid EP4 receptor is involved in suppression of 3T3-L1 adipocyte differentiation. Biochem Biophys Res Commun 2004, 322:1066-1072.
145. Blaser M., Atherton J. Helicobacter pylori persistence: biology and disease. J Clin Invest 2004, 113:321-333.
146. Roper J., Francois F., Shue P.L., Mourad M.S., Pei Z., Olivares de Perez A.Z., et al. Leptin and ghrelin in relation to Helicobacter pylori status in adult males. J Clin Endocrinol Metab 2008, 93:2350-2357.
147. Murthy N.S., Mukherjee S., Ray G., Ray A. Dietary factors and cancer chemoprevention: an overview of obesity-related malignancies. J Postgrad Med 2009, 55:45-54.
148. Pais R., Silaghi H., Silaghi A.C., Rusu M.L., Dumitrascu D.L. Metabolic syndrome and risk of subsequent colorectal cancer. World J Gastroenterol 2009, 15:5141-5148.
149. Huang X.F., Chen J.Z. Obesity, the PI3K/Akt signal pathway and colon cancer. Obes Rev 2009, 10:610-616.